SREBP-‐1c, ChREBPy LXR…
41
47.
Adiels, M., Westerbacka, J., Soro-‐Paavonen, A. y col. 2007. Acute suppression of VLDL1
secretion rate by insulin is associated with hepatic fat content and insulin resistance.
Diabetologia50, 2356-‐2365.
48.
Choi, S.H., Ginsberg, H.N., 2011. Increased very lowdensity lipoprotein (VLDL) secretion,
hepatic steatosis, and insulinresistance. TrendsEndocrinolMetab22, 353-‐363.
49.
Day, C.P., James, O.F., 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology 114,
842-‐845.
50.
Trauner, M., Arrese, M., Wagner, M., 2010. Fatty liver and lipotoxicity. Biochim
BiophysActa1801, 299-‐310.
51.
Pérez-‐Carreras, M., Del Hoyo, P., Martín, M.A. y col. 2003. Defective hepaticmitochondrial
respiratorychain inpatientswithnonalcoholic steatohepatitis. Hepatology38, 999-‐1007.
52.
Garcia-‐Ruiz, C., Fernandez-‐Checa, J.C., 2006. Mitochondrial glutathione: hepatocellular
survival-‐deathswitch. JGastroenterolHepatol 21Suppl 3, S3-‐6.
53.
Maher, J.M., 2006.Mechanismsof liver injurydue to fat", AASLDPostgrad. CourseSyllabus,
p.89-‐96.
54.
Pessayre, D., Fromenty, B., 2005. NASH: amitochondrial disease. JHepatol 42, 928-‐940.
55.
Grieco, A., Forgione, A.,Miele, L. y col. 2005. Fatty liver anddrugs. EurRevMedPharmacol
Sci 9, 261-‐263.
56.
Wieckowska, A., Zein, N.N., Yerian, L.M. y col. 2006. In vivo assessment of liver cell
apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
Hepatology44, 27-‐33.
57.
Carter-‐Kent, C., Zein, N.N., Feldstein, A.E., 2008. Cytokines in thepathogenesis of fatty liver
anddisease progression to steatohepatitis: implications for treatment. AmJ Gastroenterol
103, 1036-‐1042.
58.
Feldstein, A.E., 2010. Novel insights into the pathophysiology of nonalcoholic fatty liver
disease. SeminLiverDis30, 391-‐401.
59.
Stienstra, R., Saudale, F., Duval, C. y col. 2010. Kupffer cells promote hepatic steatosis via
interleukin-‐1beta-‐dependent suppression of peroxisome proliferator-‐activated receptor
alphaactivity. Hepatology51, 511-‐522.
60.
Leonarduzzi, G., Scavazza, A., Biasi, F. y col. 1997. The lipid peroxidation end product 4-‐
hydroxy-‐2,3-‐nonenal up-‐regulates transforming growth factor beta1 expression in the
macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 11, 851-‐
857.
61.
Kaplowitz, N., Than, T.A., Shinohara,M., Ji, C., 2007. Endoplasmic reticulumstress and liver
injury. SeminLiverDis27, 367-‐377.
62.
Kammoun, H.L., Hainault, I., Ferré, P., Foufelle, F., 2009. Nutritional related liver disease:
targeting theendoplasmic reticulumstress. CurrOpinClinNutrMetabCare12, 575-‐582.
63.
Ron, D.,Walter, P., 2007. Signal integration in the endoplasmic reticulumunfoldedprotein
response. NatRevMol Cell Biol 8, 519-‐529.
64.
Gentile, C.L., Frye, M., Pagliassotti, M.J., 2011. Endoplasmic reticulum stress and the
unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal 15,
505-‐521.
65.
Wang, D., Wei, Y., Pagliassotti, M.J., 2006. Saturated fatty acids promote endoplasmic
reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147, 943-‐
951.
66.
Schenk, S., Saberi, M., Olefsky, J.M., 2008. Insulin sensitivity: modulation by nutrients and
inflammation. J Clin Invest 118, 2992-‐3002.
67.
Yamauchi, T., Kamon, J., Ito, Y. y col. 2003. Cloning of adiponectin receptors that mediate
antidiabeticmetaboliceffects. Nature423, 762-‐769.
68.
Yamauchi, T., Kamon, J., Minokoshi, Y. y col. 2002. Adiponectin stimulates glucose
utilization and fatty-‐acidoxidationby activatingAMP-‐activatedproteinkinase. NatMed8,
1288-‐1295.
69.
Wu, X., Mahadev, K., Fuchsel, L. y col. 2007. Adiponectin suppresses IkappaB kinase
activation inducedby tumor necrosis factor-‐alphaor highglucose inendothelial cells: role
of cAMPandAMPkinase signaling. AmJ Physiol EndocrinolMetab293, E1836-‐1844.
70.
Xu, A., Wang, Y., Keshaw, H. y col. 2003. The fat-‐derived hormone adiponectin alleviates
alcoholicandnonalcoholic fatty liverdiseases inmice. J Clin Invest 112, 91-‐100.
